Back to top

Image: Bigstock

Should You Continue to Hold Medtronic Stock in Your Portfolio?

Read MoreHide Full Article

Key Takeaways

  • Medtronic's MedSurg growth is accelerating, fueled by Hugo adoption and digital surgery advancements.
  • MDT's International revenues rose 11.6% organically, thanks to product launches and regulatory approvals.
  • MDT's Neuroscience growth is gaining traction, while macroeconomic woes, product mix and FX pose risks.

Medtronic plc (MDT - Free Report) is poised for continued MedSurg growth, driven by expanding Hugo adoption, digital surgery advancements and strength in core procedural technologies. The company’s international growth is supported by new product launches, regulatory approvals and expanding commercial reach across key markets. New product launches, stronger Altaviva adoption and portfolio additions are driving growth across Medtronic’s Neuroscience business. However, macroeconomic pressures, product mix headwinds and foreign exchange fluctuations could weigh on the company’s financial performance.

Over the past year, this Zacks Rank #3 (Hold) stock has gained 1.6% against the industry’s 21.2% decline. The S&P 500 composite has returned 11.5% in the same time frame.

The renowned medical device company has a market capitalization of $131.60 billion. Medtronic has an earnings yield of 5.8% compared with the industry’s 3% yield. MDT’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 2.76%.

Let’s delve deeper.

Tailwinds for MDT

MedSurg Growth Prospects Remain Favorable: Medical Surgical is benefiting from broader adoption of robotics, digital surgery and core procedural technologies. First-quarter fiscal 2027 revenues increased 10.2% organically compared with 2.9% growth in fiscal 2026. Surgical & Endoscopy rose 9%, supported by Advanced Energy, Wound Management, Endoscopy and a larger Hugo contribution. Management expects Hugo to exceed 50,000 completed procedures by fiscal 2027 year-end, with procedure growth running at more than twice the market rate. Touch Surgery is now used in more than 1,500 operating rooms globally, while FDA clearance for Touch Surgery Aide expands the digital surgery platform. The Cornerstone Robotics agreement further broadens Medtronic’s robotics offering and is expected to contribute to growth and margins beginning in fiscal 2028. Acute Care & Monitoring grew 14.2% organically in the first quarter, although management expects growth to normalize as fiscal 2027 progresses.

Zacks Investment Research
Image Source: Zacks Investment Research

International Expansion Continues: Medtronic’s global presence remains an important growth driver as product launches and commercial expansion broaden its reach across key markets. In the fiscal first quarter, international revenues grew 11.6% organically, with Cardiovascular up 13.7%, Medical Surgical up 9.5% and Neuroscience up 6.8%. Growth was supported by continued rollout of newer technologies across regions. Medtronic launched PulseSelect in India, expanded McGRATH MAC+ across several international markets and secured CE Mark for Stealth AXiS in ENT indications. Affera and Sphere-9 also received an expanded CE Mark for ventricular arrhythmias, including ventricular tachycardia. In robotics, Hugo continues to gain procedural traction globally, while the Cornerstone Robotics partnership is intended to extend Medtronic’s reach in select markets outside the United States. These launches and regulatory approvals expand the company’s addressable market and support a broader international contribution to long-term growth.

Neuroscience Portfolio Shows Growth Prospects: Medtronic’s Neuroscience portfolio is benefiting from broader contributions across Cranial & Spinal Technologies (CST), Specialty Therapies and selected neuromodulation adjacencies. In the fiscal first quarter, Neuroscience revenues rose 9.3% organically compared with 3.1% growth in fiscal 2026. CST was a key contributor, supported by Core Spine, Neurosurgery and the first full quarter of Stealth AXiS commercialization. Specialty Therapies also contributed to growth, with Pelvic Health benefiting from rising Altaviva adoption. Neurovascular gained support from Neuroguard, Artisse and the August 2026 FDA approval of Onyx 12 for MMA embolization, while the Scientia acquisition adds differentiated guidewire technology. Neuromodulation remained softer, but SPR Therapeutics and the ViaVerte distribution agreement broaden Medtronic’s chronic pain portfolio. Management expects Neurovascular growth to reach the mid-single digits in the second half of fiscal 2027.

Downsides for MDT

Macroeconomic and Margin Risks Persist: Medtronic remains exposed to changing global trade policies, inflation and geopolitical disruption, which can raise operating costs and complicate margin recovery. Tariffs were only a slight drag in first-quarter fiscal 2027 as payments were largely offset by refunds, but the benefit may not persist as trade policies evolve. Product mix also remained unfavorable by 50 bps, mainly due to Diabetes and CAS. Pricing and cost of goods sold efficiency provided offsets during the quarter, yet continued investment in commercialization and portfolio expansion could absorb part of those gains.

Exposure to Currency Movement: Medtronic’s large international presence leaves reported results sensitive to exchange rates. Fiscal 2027 guidance now assumes a $50 million to $150 million revenue drag from foreign exchange, while the EPS impact is expected to be neutral to a 1% benefit.

MDT Stock Estimate Trend

The Zacks Consensus Estimate for Medtronic’s fiscal 2027 earnings per share (EPS) has remained constant at $5.98 in the past 30 days.

The consensus estimate for the company’s fiscal 2027 revenues is pegged at $39.03 billion, implying a 7.3% increase from the year-ago reported number.

Key Picks

Some better-ranked stocks in the broader medical space are Bausch + Lomb Corp. (BLCO - Free Report) , IDEXX Laboratories (IDXX - Free Report) and Insulet (PODD - Free Report) .

Bausch + Lomb has an estimated long-term growth rate of 40.1%, compared to the industry’s 15.2% growth. Shares of the company have rallied 42.6% compared with the industry’s 12% growth over the past year. BLCO’s earnings outpaced estimates in two of the trailing four quarters, matched once and missed on another occasion, the average surprise being 21.67%. 

BLCO sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

IDEXX Laboratories, carrying a Zacks Rank #2 (Buy), has an earnings yield of 2.2% against the industry’s negative 2.3% yield. Its earnings beat estimates in each of the trailing four quarters, the average surprise being 5.5%. IDXX shares have dipped 1% against the industry’s 3.4% growth over the past year.

Insulet, carrying a Zacks Rank #2, has an estimated long-term growth rate of 19.4%, compared to the industry’s 9.3% growth. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 17.43%. PODD shares have dipped 58% compared to the industry’s 20.4% decline over the past year.

Published in